Tag: Opdivo
Bristol-Myers: A BLA accepted for subcutaneous Opdivo
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Bristol Myers: positive trial for subcutaneous Opdivo
(CercleFinance.com) – Bristol Myers presented data this weekend from a phase 3 trial evaluating the subcutaneous formulation of Opdivo (nivolumab) versus intravenous (IV) Opdivo in patients with advanced or metastatic…
Bristol Myers: Positive trial for subcutaneous Opdivo
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Bristol Myers:presents Opdivo treatment at ASCO GU 2024
(CercleFinance.com) – Bristol Myers Squibb presents transformative research in the treatment of genitourinary cancers at ASCO GU 2024. The group presents the first presentation of results from the phase 3…
Bristol Myers: Priority review obtained for Opdivo
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Bristol Myers: Opdivo has been approved by the FDA
(CercleFinance.com) – Bristol Myers Squibb announced that Opdivo (nivolumab) has been approved by the United States Food and Drug Administration (FDA) for the adjuvant treatment of adult and pediatric patients…
Ipsen: new for Cabometyx in combination with Opdivo
(Boursier.com) — Ipsen announced the results of analyzes from the Phase III CheckMate -9ER study over a two-year follow-up period (25.4 months minimum; median 32.9 months), which demonstrated sustained benefits…
Ipsen: Combined with Opdivo, Cabometyx improves survival for kidney cancer patients
PARIS (Agefi-Dow Jones)–The pharmaceutical group Ipsen on Tuesday announced the results of analyzes of the phase 3 CheckMate -9ER study, which demonstrated sustained benefits in terms of survival and response…